Goldman Sachs, Jefferies Initiate Manipal Health With Buy; JPMorgan Goes Neutral

The Quick Take

• Goldman Sachs and Jefferies initiated Manipal Health coverage with Buy ratings, while JPMorgan went Neutral
• Goldman estimates Manipal acquired more than 5,500 beds over five to six years — more than its next five competitors combined
• Split analyst view creates a valuation debate as Manipal's aggressive acquisition strategy enters a key profitability phase

Manipal Health Enterprises has attracted contrasting analyst views at its latest round of initiations, with Goldman Sachs and Jefferies both assigning Buy ratings while JPMorgan opted for a more cautious Neutral stance. The divergence reflects differing assessments of whether Manipal's relentless acquisition-driven bed expansion has already been priced in, or still offers a meaningful earnings growth runway.

Goldman Sachs estimates Manipal has added more than 5,500 beds over five to six years — a figure that dwarfs the combined capacity additions of its next five peers. This structural scale advantage positions Manipal as the dominant private hospital consolidator in India, enabling negotiating power with insurers, optimised clinical throughput, and brand leverage in premium urban catchments where ARPU is highest.

The key watch item is whether the acquired bed stock converts into measurable EBITDA margin improvement over the next four to six quarters. High-occupancy mature units subsidising newer greenfield beds is a common pattern in Indian hospital expansion, and JPMorgan's Neutral likely prices in this near-term dilution risk. A sustained occupancy improvement above the 60-65% threshold at acquired hospitals would be the catalyst to close the bull-bear gap.

Synthesized from 1 source.